In last trading session, Denali Therapeutics Inc (NASDAQ:DNLI) saw 2.06 million shares changing hands with its beta currently measuring 1.53. Company’s recent per share price level of $15.95 trading at $0.91 or 6.05% at ring of the bell on the day assigns it a market valuation of $2.32B. That closing price of DNLI’s stock is at a discount of -108.97% from its 52-week high price of $33.33 and is indicating a premium of 12.16% from its 52-week low price of $14.01. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.84 million shares which gives us an average trading volume of 1.10 million if we extend that period to 3-months.
For Denali Therapeutics Inc (DNLI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.17. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.71 in the current quarter.
Denali Therapeutics Inc (NASDAQ:DNLI) trade information
Upright in the green during last session for gaining 6.05%, in the last five days DNLI remained trading in the red while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $15.95 price level, adding 6.01% to its value on the day. Denali Therapeutics Inc’s shares saw a change of -21.74% in year-to-date performance and have moved -2.15% in past 5-day. Denali Therapeutics Inc (NASDAQ:DNLI) showed a performance of -23.61% in past 30-days. Number of shares sold short was 8.89 million shares which calculate 10.01 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 38.5 to the stock, which implies a rise of 58.57% to its current value. Analysts have been projecting 32 as a low price target for the stock while placing it at a high target of 45. It follows that stock’s current price would drop -100.63% in reaching the projected high whereas dropping to the targeted low would mean a loss of -100.63% for stock’s current value.
11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 3.24M for the same. And 11 analysts are in estimates of company making revenue of 7.79M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -4.46% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -12.76% while estimates for its earnings growth in next 5 years are of 7.03%.
Denali Therapeutics Inc (NASDAQ:DNLI)’s Major holders
Insiders are in possession of 9.58% of company’s total shares while institution are holding 90.98 percent of that, with stock having share float percentage of 100.62%. Investors also watch the number of corporate investors in a company very closely, which is 90.98% institutions for Denali Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at DNLI for having 13.17 million shares of worth $305.91 million. And as of 2024-06-30, it was holding 8.8181 of the company’s outstanding shares.
The second largest institutional holder is BAILLIE GIFFORD & CO, which was holding about 13.76 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.1523 of outstanding shares, having a total worth of $319.59 million.
